Investors

BioVinc LLC (BV) discovered a novel skeletal selective therapy for life threatening orthopedic infections and osteomyelitis, and has demonstrated the product OsteoFloxacin^TM is the only antibiotic known to kill the deadly methicillin-resistant Staphylococcus aureus (MRSA) within mature bone biofilms.¹ Thus eradication of incurable MRSA infected implants, which often leads to amputation and death, is now possible. In addition, treatment costs averaging >$100,000 per patient will be reduced by avoiding lengthy hospitalizations, serious complications, and readmissions. The company is now positioned to complete regulatory studies and initiate Phase 1 clinical trials in less than two years. BioVinc is seeking a milestone driven investment to secure first in human studies for OsteoFloxacin^TM.